SAGE has launched the seventh journal in its highly successful Therapeutic Advances series: Therapeutic Advances in Musculoskeletal Disease.
Aimed at all professionals concerned with research into, and the practice of, musculoskeletal disease, the journal is a forum for all views on related subjects. The journal offers rapid peer-review and publication, with manuscripts published online within 7 weeks of acceptance. The editors welcome original research and review articles of latest advances in the treatment of arthropathies and other joint disorders, systemic connective tissue disorders, dorsopathies, soft tissue disorders, osteopathies and chondropathies.
We’re very pleased to have on board as Editor-in-Chief Philip Sambrook OAM. Philip has published over 270 peer reviewed papers including invited editorials in the New England Journal of Medicine, British Medical Journal and The Lancet. He is also the current President of the Australian & New Zealand Bone & Mineral Society, on the Committee of Scientific Advisors of The International Osteoporosis Foundation, and on the Board of the International Bone and Mineral Society.
“Musculoskeletal disease is affecting an increasing proportion of our aging population – the chronic diseases it includes have led to many new categories of medical treatments that are changing the way we manage patients,” Philip said. “While there are many journals in this growing area, we still need to have more avenues to publish and access the material. For this reason, I am enthusiastic about leading the launch of this new journal.”
Launching new journals continues to be challenging, but the impact that this series has made indicates there is still demand for access to timely peer-reviewed content in therapeutic treatments.